IBJNews

Uncertainty over drug pipeline sends Lilly shares down

Back to TopCommentsE-mailPrintBookmark and Share

Investors and analysts appear increasingly impatient for Eli Lilly and Co. to provide a more concrete plan to address its looming patent expirations.

So even after Lilly’s third-quarter profit soared 22 percent and it raised its year-end profit forecast, the company’s stock price slipped 3 percent in morning trading.

“The pipeline remains lackluster,” Les Funtleyder, a health care analyst at Miller Tabak & Co. in New York, wrote in a note to investors.

For the first time publicly, Lilly officials admitted the obvious: Their pipeline products aren’t likely to offset the revenue the company will lose its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity in 2011 and 2013, respectively.

"They may not be there in time to recover immediately from the Zyprexa-Cymbalta hit,” Chief Financial Officer Derica Rice said during a conference call today with analysts. Several analysts pressed Lilly for details on how quickly certain pipeline drugs can develop or whether Lilly is now open to a big merger as a fallback strategy.

Lilly officials, as they have always done, resisted talk of a big merger.

Rice said the pipeline "is where our focus is at this time, and it’s not on large-scale M&A."

In its third quarter, Lilly earned nearly $942 million, or 86 cents per share, compared with a loss of $466 million, or 43 cents per share, in the same quarter a year ago.

The year-ago loss resulted from Lilly's acquisition of New York-based ImClone Systems Inc. Assuming Lilly had owned ImClone for all of 2008, and excluding other extraordinary charges this year, the company would have earned $1.20 per share, an increase of 22 percent over the same quarter a year ago. On that basis, Wall Street analysts were expecting Lilly to earn $1.02 per share.

"Our performance in the third quarter once again was driven by volume-based sales growth, improving gross margins and tight control of operating expenses, allowing us to deliver very attractive earnings growth," Lilly CEO John Lechleiter said in a statement.

Lilly's revenue rose 7 percent in the quarter over the same period of 2008, to $5.56 billion.

Its strongest drug was Alimta, which treats various stages of non-small cell lung cancer. Its sales grew 47 percent compared with the third quarter last year. The antidepressant Cymbalta and the insulin drug Humalog also posted double-digits sales growth in the third quarter.

Lilly recorded a charge of 23 cents per share because it agreed last week to sell its Tippecanoe Laboratories plant in Lafayette to a German firm. That charge, before taxes, consisted of a $355 million accounting charge and $38 million in cash that Lilly will pay out to its 700 employees at Tippecanoe as severance.

The company also took a charge to abandon two phase-3 products designed to treat osteoporosis and multiple sclerosis.

So far this year, Lilly has earned $2.31 per share, excluding a charge of 6 cents per share to settle lawsuits brought by various states alleging illegal marketing of Lilly's bestseller, Zyprexa.

The company has not been issuing quarterly profit forecasts. But, in July, it predicted it would earn $4.20 to $4.30 per share for the entire year, excluding special charges. Today it raised that forecast to a range of $4.30 to $.40 per share, excluding special items.

Lilly’s shares traded as low as $34.06 this morning, down 3.3 percent. They are off roughly 13 percent so far this year.

ADVERTISEMENT

  • seriously
    Trust me Daniel, we're all looking forward to the resolution of your claim.
  • Zyprexa profits
    Eli Lilly has been around for a century,and a proven performer.I am waiting to see how they resolve the costly Zyprexa saga.

    Great news that Eli Lilly is posting profit,as a Zyprexa damage claimant who got diabetes from it I know that Lilly can afford to pay me my settlement.

    ----
    Daniel Haszard

    Post a comment to this story

    COMMENTS POLICY
    We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
     
    You are legally responsible for what you post and your anonymity is not guaranteed.
     
    Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
     
    No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
     
    We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
     

    Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

    Sponsored by
    ADVERTISEMENT

    facebook - twitter on Facebook & Twitter

    Follow on TwitterFollow IBJ on Facebook:
    Follow on TwitterFollow IBJ's Tweets on these topics:
     
    Subscribe to IBJ
    1. How much you wanna bet, that 70% of the jobs created there (after construction) are minimum wage? And Harvey is correct, the vast majority of residents in this project will drive to their jobs, and to think otherwise, is like Harvey says, a pipe dream. Someone working at a restaurant or retail store will not be able to afford living there. What ever happened to people who wanted to build buildings, paying for it themselves? Not a fan of these tax deals.

    2. Uh, no GeorgeP. The project is supposed to bring on 1,000 jobs and those people along with the people that will be living in the new residential will be driving to their jobs. The walkable stuff is a pipe dream. Besides, walkable is defined as having all daily necessities within 1/2 mile. That's not the case here. Never will be.

    3. Brad is on to something there. The merger of the Formula E and IndyCar Series would give IndyCar access to International markets and Formula E access the Indianapolis 500, not to mention some other events in the USA. Maybe after 2016 but before the new Dallara is rolled out for 2018. This give IndyCar two more seasons to run the DW12 and Formula E to get charged up, pun intended. Then shock the racing world, pun intended, but making the 101st Indianapolis 500 a stellar, groundbreaking event: The first all-electric Indy 500, and use that platform to promote the future of the sport.

    4. No, HarveyF, the exact opposite. Greater density and closeness to retail and everyday necessities reduces traffic. When one has to drive miles for necessities, all those cars are on the roads for many miles. When reasonable density is built, low rise in this case, in the middle of a thriving retail area, one has to drive far less, actually reducing the number of cars on the road.

    5. The Indy Star announced today the appointment of a new Beverage Reporter! So instead of insightful reports on Indy pro sports and Indiana college teams, you now get to read stories about the 432nd new brewery open or some obscure Hoosier winery winning a county fair blue ribbon. Yep, that's the coverage we Star readers crave. Not.

    ADVERTISEMENT